Literature DB >> 23998544

Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention.

Yuichiro Kitai1, Neiko Ozasa, Takeshi Morimoto, Bingyuan Bao, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Motoko Yanagita, Satoshi Shizuta, Takeshi Kimura.   

Abstract

BACKGROUND: Little is known about the prognostic implications of anemia in patients undergoing elective percutaneous coronary intervention (PCI), especially when they have coexisting chronic kidney disease (CKD).
METHODS: We identified 7299 patients who underwent elective PCI from the CREDO-Kyoto registry cohort-2. The primary outcome was 3-year major adverse cardiac events (MACE); composite of all cause death, heart failure hospitalization, and myocardial infarction.
RESULTS: In total, 1466 patients (20.0%) had mild anemia (hemoglobin=11.0-11.9 g/dL for women and 11.0-12.9 g/dL for men), and 740 patients (10.1%) had moderate-to-severe anemia (hemoglobin<11.0 g/dL both for women and for men). Compared to the no-anemia group, cumulative incidence of MACE was significantly higher in the mild and moderate-to-severe anemia groups (7.9%, 20.1%, and 34.2%, respectively). The adjusted hazard ratios of mild and moderate-to-severe anemia versus no-anemia for MACE were 1.77 (95% confidence interval: 1.47-2.15) and 2.53 (95% confidence interval: 2.03-3.14), respectively. In a subgroup analysis, significantly higher risk for MACE was consistently observed with mild and moderate-to-severe anemia both in patients with and without CKD. The risk for MACE showed an accretive increment with exacerbation in either the renal function or anemia (interaction p<0.001).
CONCLUSIONS: Even mild anemia was associated with significantly worse 3-year clinical outcomes in patients who underwent elective PCI. Coexisting CKD additively increased the risk for MACE in these patients.
© 2013.

Entities:  

Keywords:  Anemia; Chronic kidney disease; Coronary artery disease; Prognosis

Mesh:

Year:  2013        PMID: 23998544     DOI: 10.1016/j.ijcard.2013.08.029

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  Impact of red blood cells count on the relationship between high density lipoproteins and the prevalence and extent of coronary artery disease: a single centre study [corrected].

Authors:  Alon Schaffer; Monica Verdoia; Ettore Cassetti; Lucia Barbieri; Pasquale Perrone-Filardi; Paolo Marino; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

2.  Impacts of anemia on 3-year ischemic events in patients undergoing percutaneous coronary intervention: a propensity-matched study.

Authors:  Xiaoyan Wang; Miaohan Qiu; Jing Li; Heyang Wang; Jing Qi; Geng Wang; Kai Xu; Haiwei Liu; Xin Zhao; Quanmin Jing; Yi Li; Yaling Han
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

3.  Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis.

Authors:  Xiaoyan Wang; Miaohan Qiu; Jing Qi; Jing Li; Heyang Wang; Yi Li; Yaling Han
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

4.  Long term prognosis of acute coronary syndrome with chronic renal dysfunction treated in different therapy units at department of cardiology: a retrospective cohort study.

Authors:  Cong Fu; Zulong Sheng; Yuyu Yao; Xin Wang; Chaojun Yu; Genshan Ma
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  The platelet-to-lymphocyte ratio as a predictor of all-cause mortality in patients with coronary artery disease undergoing elective percutaneous coronary intervention and stent implantation.

Authors:  Tadeusz Osadnik; Jarosław Wasilewski; Andrzej Lekston; Joanna Strzelczyk; Anna Kurek; Małgorzata Gonera; Marcin Gawlita; Rafał Reguła; Kamil Bujak; Bożena Szyguła-Jurkiewicz; Andrzej Wiczkowski; Lech Poloński
Journal:  J Saudi Heart Assoc       Date:  2015-02-17

6.  Prevalence and prognostic significance of anemia in patients presenting for ST-elevation myocardial infarction in a Tunisian center.

Authors:  Walid Jomaa; Imen Ben Ali; Sonia Hamdi; Mohamed A Azaiez; Aymen El Hraïech; Khaldoun Ben Hamda; Faouzi Maatouk
Journal:  J Saudi Heart Assoc       Date:  2016-10-20

7.  Prognostic Impact of Baseline Hemoglobin Levels on Long-Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions.

Authors:  Kazuya Nagao; Hirotoshi Watanabe; Takeshi Morimoto; Tsukasa Inada; Fujio Hayashi; Yoshihisa Nakagawa; Yutaka Furukawa; Kazushige Kadota; Takashi Akasaka; Masahiro Natsuaki; Ken Kozuma; Kengo Tanabe; Yoshihiro Morino; Hiroki Shiomi; Takeshi Kimura
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

8.  Association of the Hemoglobin to Serum Creatinine Ratio with In-Hospital Adverse Outcomes after Percutaneous Coronary Intervention among Non-Dialysis Patients: Insights from a Japanese Nationwide Registry (J-PCI Registry).

Authors:  Yohei Numasawa; Taku Inohara; Hideki Ishii; Kyohei Yamaji; Shun Kohsaka; Mitsuaki Sawano; Masaki Kodaira; Shiro Uemura; Kazushige Kadota; Tetsuya Amano; Masato Nakamura; Yuji Ikari
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

9.  Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease.

Authors:  Tadeusz Osadnik; Joanna Strzelczyk; Michał Hawranek; Andrzej Lekston; Jarosław Wasilewski; Anna Kurek; Aleksander Rafał Gutowski; Krzysztof Wilczek; Krzysztof Dyrbuś; Marek Gierlotka; Andrzej Wiczkowski; Mariusz Gąsior; Andrzej Szafranek; Lech Poloński
Journal:  BMC Cardiovasc Disord       Date:  2013-12-10       Impact factor: 2.298

10.  Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry.

Authors:  Marja Puurunen; Tuomas Kiviniemi; Wail Nammas; Axel Schlitt; Andrea Rubboli; Kai Nyman; Pasi Karjalainen; Paulus Kirchhof; Gregory Y H Lip; Juhani K E Airaksinen
Journal:  BMJ Open       Date:  2014-05-13       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.